ZYMEWORKS INC. - COMMON STOCK

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

05 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

26 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

25 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

13 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

08 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

12 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 Nov 2024 05:05:00 By Nasdaq GlobeNewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

21 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

05 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

31 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

29 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

25 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

21 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

10 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

18 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

03 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

22 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

01 Aug 2024 15:10:51 By Nasdaq GlobeNewswire